Twist Bioscience (TWST)
(Real Time Quote from BATS)
$52.15 USD
-1.41 (-2.63%)
Updated Jul 19, 2024 11:30 AM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TWST 52.15 -1.41(-2.63%)
Will TWST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TWST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TWST
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
TWST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Other News for TWST
Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
Twist Bioscience says first patient dosed in Pure Biologics' BA-0405 study
Buy Rating Justified by Strong Demand and Strategic Expansion of Twist Bioscience’s Express Genes
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies